2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-117984
    RU 35929 111711-47-8 98%
    RU 35929 is a nootropic agent. RU 35929 enhances learning and memory.
    RU 35929
  • HY-117993
    MIND4 1639965-26-6 98%
    MIND4 is a neuroprotective thiozoline compound that inhibits the deacetylase SIRT2. MIND4 is also an inducer and activator of the nuclear factor NRF2. MIND4 can induce NRF2 activation in neurons and non-neuronal cells and reduce the production of reactive oxygen and nitrogen intermediates.
    MIND4
  • HY-118008
    Lesopitron 132449-46-8 98%
    Lesopitron (E-4424) is a 5-HT receptor agonist with potent anxiolytic-like effects. Lesopitron inhibits forskolin-stimulated adenylate cyclase activity with an IC50 value of 125 nM.
    Lesopitron
  • HY-118018
    CHF-2993 202914-21-4 98%
    CHF-2993 is an orally active anticonvulsant. CHF-2993 antagonizes Bicuculline (HY-N0219)- and Picrotoxin (HY-101391)-induced tonic convulsions in mice, shows no activity against Pentylenetetrazole-induced clonic convulsions in mice, and partially reduces Veratridine (HY-N6691)-induced aspartate efflux in rat cortical synaptosomes. CHF-2993 can be used in the research of epilepsy.
    CHF-2993
  • HY-118022
    VU0361747 1309976-66-6 98%
    VU0361747 is a potent and selective positive allosteric modulator of metabotropic glutamate receptor 4 (mGluR4 PAM). VU0361737 has neuroprotective effect. VU0361737 significantly reverses Amphetamine-induced hyperlocomotion in vivo.
    VU0361747
  • HY-118030
    RQ-00311651 1257116-00-9 98%
    RQ-00311651 is a T-type calcium channel blocker that specifically targets the Cav3.2 isoform with a role in neuropathic and visceral pain. RQ-00311651 significantly inhibits T currents in HEK293 cells expressing human Cav3.1 or Cav3.2. RQ-00311651 also inhibited high potassium-induced calcium signaling. RQ-00311651 also inhibits antiallergic properties in rats and mice with neuropathic pain induced by spinal nerve injury or Paclitaxel (HY-B0015). Oral and intraperitoneal injection (10-20 mg/kg) inhibits Cerulein (HY-A0190)-induced acute pancreatitis and cyclophosphamide-induced cystitis in mice.
    RQ-00311651
  • HY-118064
    (R)-Thionisoxetine 163059-33-4 98%
    (R)-Thionisoxetine is a potent and selective inhibitor of central and peripheral norepinephrine (NE) uptake. (R)-thionisoxetine prevented hypothalamic NE depletion by 6-hydroxydopamine with an ED50 of 0.21 mg/kg. (R)-Thionisoxetine can be used for the research of a variety of diseases including depression and urinary incontinence.
    (R)-Thionisoxetine
  • HY-118072
    Aspalatone 147249-33-0 98.40%
    Aspalatone is an orally active antiplatelet aggregant with IC50 of 180 μM. Aspalatone has antioxidant and neuroprotective activities.
    Aspalatone
  • HY-118127
    Rilapine 79781-95-6 98%
    Rilapine is an atypical antipsychotic agent.
    Rilapine
  • HY-118160
    PPM-18 65240-86-0 99.17%
    PPM-18 (NSC 73233) is a Vitamin K (HY-B2172) analog. PPM-18 prevents LPS-induced IκBα degradation, thereby inhibiting NF-κB activation and nuclear translocation of NF-κB. PPM-18 inhibits LPS-induced nitrite production and iNOS expression. PPM-18 inhibits HDAC6. PPM-18 induces ROS accumulation, activates AMPK, inhibits the mTORC1 and PI3K/AKT pathways, initiates Autophagy, and induces Apoptosis. PPM-18 suppresses seizures in zebrafish and mouse epilepsy models. PPM-18 prevents LPS-induced lethal toxicity and delayed hypotension. PPM-18 exhibits anticancer activity against leukemia and bladder cancer. PPM-18 can be used in research related to septic shock, bladder cancer and atherosclerosis.
    PPM-18
  • HY-118182
    Tidembersat 175013-73-7 98%
    Tidembersat (Example 4) is a benzopyran derivative that can be used in the research of a variety of CNS disorders and traumatic brain injury.
    Tidembersat
  • HY-118200
    BRL-41992 124097-52-5 98%
    BRL-41992 is a selective α₂B-adrenergic receptor antagonist. BRL-41992 exhibits 94-fold higher selectivity for the α₂B-receptor than for the α₂A-receptor with Kᵢ values in neonatal rat lung tissue (expressing the α₂B-receptor) and in human platelet membranes (expressing the α₂A-receptor) of 1.1 and 103.3 nM. BRL-41992 can be used to verify the functional differences of α₂ receptor subtypes.
    BRL-41992
  • HY-118222
    KBR 2822 126988-60-1 98%
    KBR 2822 is an inhibitor of neurological target esterase (NTE) and has an inhibitory effect on AChE. KBR 2822 can aggravate neurological damage under certain conditions, but does not cause neurological disease when used alone in the absence of direct neurotoxicity or biochemical damage.
    KBR 2822
  • HY-118238
    Remeglurant 1309783-00-3 98%
    Remeglurant (MRZ-8456) acts as a selective, orally active and allosteric antagonist of the mGlu5 receptor, with an IC50 of 13 nM. Remeglurant (MRZ-8456) can be used in the research for dyskinesia in Parkinson’s disease (PD).
    Remeglurant
  • HY-118249
    GSK 1997132B 1168138-37-1 98%
    GSK 1997132B is a benzimidazole-based PPARγ partial agonist that can cross the blood-brain barrier with a pEC50 value of 8.0. GSK 1997132B has no significant effect on PPARα/δ. GSK 1997132B improves the problem of high blood clearance rate of earlier compounds, avoiding side effects such as weight gain and edema. GSK 1997132B can be used for research on Alzheimer's disease.
    GSK 1997132B
  • HY-118256
    LSN2814617 1313498-17-7 98%
    LSN2814617 is an orally active, potent, brain-penetrant, and selective mGlu5 (metabotropic glutamate 5) positive allosteric modulator (PAM), with EC50 values of 52 nM (Human mGlu5) and 42 nM (rat mGlu5). LSN2814617 shows wake-promoting effect. LSN2814617 can be used for schizophrenia research.
    LSN2814617
  • HY-118259
    L-663581 122384-14-9 98%
    L-663581 (FG-8205) is an agonist of benzodiazepine receptor, acting as a partial agonist at GABA A receptor.
    L-663581
  • HY-118308
    AHN-683 143934-15-0 98%
    AHN-683 is a luciferin-derived ligand that targets the peripheral benzodiazepine receptor (BDR).
    AHN-683
  • HY-118347
    Aspartame acesulfame 106372-55-8 98%
    Aspartame acesulfame is a methyl ester of a dipeptide. Aspartame acesulfame can be used as a synthetic nonnutritive sweetener. Aspartame acesulfame is composed of phenylalanine (50%), aspartic acid (40%) and methanol (10%).
    Aspartame acesulfame
  • HY-118350
    FR 75513 127975-78-4 98%
    FR 75513 is a 1,1'-biphenyl-2,6-dicarboxylic acid diester series compound that can inhibit the contraction of the detrusor muscle of guinea pig bladder (IC50=3.3 μg/mL). After intravenous injection of FR 75513 into anesthetized rats, it also showed strong inhibitory activity on the detrusor contraction (ID50=0.04 mg/kg).
    FR 75513
Cat. No. Product Name / Synonyms Application Reactivity